companydata.dkcompanydata.dk

Nykode Therapeutics Denmark A/S: Financial statements 2021

CVR: 42038660

Source: annual report 2021, Danish Business Authority

08/01/2021 – 31/12/2021

Nykode Therapeutics Denmark A/S (CVR 42038660) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 10,590,585 and a net result of DKK 578,082. Equity in the 2021 report amounted to DKK 978,082. The solvency ratio was 8.9%. The company had 7 employees in the financial year.

Gross Profit
DKK 10,590,585
Profit/Loss
DKK 578,082
Equity
DKK 978,082
Total Assets
DKK 10,953,602
Employees
7

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Nykode Therapeutics Denmark A/S

Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.

Try the lead list generator

Events in 2021

Vaccibody Denmark A/S changes name to Nykode Therapeutics Denmark A/SDec 20, 2021

On December 20, 2021, the company changed its name from Vaccibody Denmark A/S to Nykode Therapeutics Denmark A/S.

Katrine Hovgaard Husum joins the board of Nykode Therapeutics Denmark A/SApr 21, 2021

As of April 21, 2021, Katrine Hovgaard Husum has joined the board of directors of Nykode Therapeutics Denmark A/S.

Lars Dencker Nielsen leaves the board of Nykode Therapeutics Denmark A/SApr 21, 2021

As of April 21, 2021, Lars Dencker Nielsen has left the board of directors of Nykode Therapeutics Denmark A/S.

Nykode Therapeutics Denmark A/S appoints new auditorJan 8, 2021

As of January 8, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Nykode Therapeutics Denmark A/S.

Lars Dencker Nielsen joins the board of Nykode Therapeutics Denmark A/SJan 8, 2021

As of January 8, 2021, Lars Dencker Nielsen has joined the board of directors of Nykode Therapeutics Denmark A/S.

Michael Thyrring Engsig joins the board of Nykode Therapeutics Denmark A/SJan 8, 2021

As of January 8, 2021, Michael Thyrring Engsig has joined the board of directors of Nykode Therapeutics Denmark A/S.

Anders Tuv joins the board of Nykode Therapeutics Denmark A/SJan 8, 2021

As of January 8, 2021, Anders Tuv has joined the board of directors of Nykode Therapeutics Denmark A/S.

Michael Thyrring Engsig joins Nykode Therapeutics Denmark A/S as directorJan 8, 2021

As of January 8, 2021, Michael Thyrring Engsig is registered as director of Nykode Therapeutics Denmark A/S.

Registered as owner of Nykode Therapeutics Denmark A/SJan 8, 2021

As of January 8, 2021, is registered as an owner of Nykode Therapeutics Denmark A/S with an ownership share of 100%.

Nykode Therapeutics Denmark A/S is foundedJan 8, 2021

Nykode Therapeutics Denmark A/S was founded on January 8, 2021.

About Nykode Therapeutics Denmark A/S

Nykode Therapeutics Denmark A/S is a Danish company of the type Aktieselskab based in Kongens Lyngby, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named Vaccibody Denmark A/S. The management consists of Michael Thyrring Engsig. The board consists of Louise Stubbe (chair), Harald Gurvin and Michael Thyrring Engsig. The company is owned by Nykode Therapeutics ASA. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 31,839,001 and a net result of DKK 1,347,127 compared with DKK 156,959 the year before. Equity in the 2025 report amounted to DKK 6,862,099.

Source: annual report 2025, Danish Business Authority

Other financial years